Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 39.60 NOK
Change Today +2.00 / 5.32%
Volume 7.9K
As of 10:25 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

photocure asa (PHO) Snapshot

Open
38.10 NOK
Previous Close
37.60 NOK
Day High
39.60 NOK
Day Low
38.00 NOK
52 Week High
05/11/15 - 44.00 NOK
52 Week Low
11/4/14 - 17.70 NOK
Market Cap
848.4M
Average Volume 10 Days
36.0K
EPS TTM
-0.99 NOK
Shares Outstanding
21.4M
EX-Date
05/23/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHOTOCURE ASA (PHO)

Related News

No related news articles were found.

photocure asa (PHO) Related Businessweek News

No Related Businessweek News Found

photocure asa (PHO) Details

Photocure ASA engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products and related technical medical equipment. The company markets Hexvix/Cysview for improved detection and management of bladder cancer. Its products pipeline includes Visonac that has completed Phase 2b study for the treatment of moderate to severe acne; Cevira, which has completed Phase 2b study for the treatment of human papilloma virus disease and precancerous lesions of the cervix; and Lumacan that is under Phase 1/2 development for the detection of colorectal cancer. The company sells its products to license partners, pharmaceutical wholesalers, and hospitals. It operates in Norway, Sweden, Denmark, Finland, and the United States. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.

47 Employees
Last Reported Date: 04/9/15
Founded in 1997

photocure asa (PHO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

photocure asa (PHO) Key Developments

BioSyent Pharma Acquires Exclusive Rights for Cysview® in Canada

BioSyent Inc. announced that its subsidiary BioSyent Pharma Inc. has signed an agreement with Photocure ASA granting BioSyent the exclusive rights for Cysview® in Canada. Cysview® (hexaminolevulinate hydro-chloride) is an innovative technology that aids in the diagnosis and management of bladder cancer and was approved by Health Canada in January 2015. It has been successfully marketed in the USA, Europe, and the Nordic region, since 2006. Commercialization of Cysview® in Canada will commence this year. Under the terms of the agreement, Photocure will receive up to $1,000,000 in milestone payments for the rights to Cysview in Canada, which includes $650,000 upon signing of the agreement.

PhotoCure ASA Appoints Biosyent Pharma Inc. as Exclusive Distributor for the Commercialization of Cysview in Canada

Photocure ASA announced the appointment of BioSyent Pharma Inc. as their exclusive distributor for the commercialization of Cysview in Canada. Under the terms of the agreement, Photocure will receive up to USD 1,000,000 in milestone payments for the rights to Cysview in the territory, which includes USD 650,000 upon signing of the agreement. BioSyent Pharma will fund all costs related to the launch and commercialization of Cysview, which was approved by Health Canada in January 2015. The market potential in the territory is estimated to be similar to the potential in the Nordics, where Photocure commercializes Hexvix with its own sales team.

Photocure ASA Reports Unaudited Group Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Revenue Guidance for the Full Year 2015

Photocure ASA reported unaudited group results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of NOK 34,787,000, operating loss of NOK 1,855,000, and loss before tax of NOK 8,091,000, net loss NOK of 10,823,000 or net loss per diluted share NOK of 0.51, net cash used in operations of NOK 2,506,000, machinery & equipment investment of NOK 204,000 against total revenues of NOK 25,508,000, operating loss of NOK 5,669,000, and loss before tax of NOK 4,206,000, net loss of NOK 4,206,000 or net loss per diluted share of NOK 0.20, net cash used in operations of NOK 9,795,000, machinery & equipment investment of NOK 256,000 for the same period last year. The company reported intangible asset investment of NOK 1,723,000. For the six months, the company reported total revenues as NOK 64,362,000, operating loss of NOK 9,061,000, and loss before tax of NOK 15,043,000, net loss of NOK 21,775,000 or net loss per diluted share of NOK 1.02, net cash used in operations of NOK 14,405,000, machinery & equipment investment of NOK 440,000 against total revenues as NOK 46,171,000, operating loss of NOK 19,418,000, and loss before tax of NOK 17,249,000, net loss of NOK 17,249,000 or net loss per diluted share of NOK 0.81, net cash used in operations of NOK 28,457,000, machinery & equipment investment of NOK 346,000 for the same period last year. The company reported intangible asset investment as NOK 7,031,000. The company expects revenues to continue to grow in 2015 driven by an increase of Hexvix/Cysview in-market unit sales of 10%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHO:NO 39.60 NOK +2.00

PHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHO.
View Industry Companies
 

Industry Analysis

PHO

Industry Average

Valuation PHO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOTOCURE ASA, please visit www.photocure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.